PERSPECTA

News from every angle

← Back to headlines

GRI Bio to Present Phase 2a IPF Drug Data at ERS Congress

GRI Bio is scheduled to present late-breaking Phase 2a data for its IPF drug, GRI-0621, at the ERS Congress. The presentation will highlight lung function, anti-fibrotic biomarkers, and favorable tolerability in patients with Idiopathic Pulmonary Fibrosis.

24 Aug, 13:05 — 24 Aug, 13:05
PostShare

Sources

Showing 1 of 2 sources
taiwan-newsMostly Factual8h ago

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 - Taiwan News

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026  Taiwan News

Read full article →

Coverage Timeline

First report: taiwan-news · 24 Aug, 13:05Full coverage: 2 · 8mWindow: 8m
Left-leaningCenterRight-leaning
taiwan-news24 Aug, 13:05First to report

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 - Taiwan News

investing-com24 Aug, 13:12Latest update

GRI Bio to present Phase 2a IPF drug data at ERS Congress

Related Stories

Cardiologist highlights key food for lowering cholesterol

42m ago

West Nile Virus Cases and Deaths Rise in Attica, Greece

1h ago

Eight-Year-Old Girl Dies from Brain-Eating Amoeba in Louisiana

3h ago

West Nile Virus Cases Rise Across Southeastern Europe

3h ago